Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer
- 21 February 2006
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 55 (12) , 1553-1564
- https://doi.org/10.1007/s00262-006-0145-7
Abstract
Purpose: A phase I/II study was conducted to investigate the safety, tolerability and clinical response to vaccination with a combination of telomerase peptides GV1001 (hTERT: 611–626) and HR2822 (hTERT: 540–548) in patients with non-small cell lung cancer. Experimental design: Twenty-six patients with non-small cell lung cancer received intradermal administrations of either 60 nmole (112 μg) or 300 nmole (560 μg) GV1001 in combination with 60 nM (68.4 μg) HR2822 and granulocyte macrophage-colony stimulating factor. The treatment period was 10 weeks. Booster vaccinations with 300 nM GV1001 were offered as follow-up. Monitoring of blood samples, clinical examination and radiological staging were performed regularly. Immune responses were measured as delayed-type hypersensitivity skin reaction and in vitro T cell proliferation. Bone marrow function was monitored in long time survivors. Results: The treatment was well tolerated with minor side effects. No bone marrow toxicities were observed in long time survivors with immune responses. Immune responses against GV1001 were detected in 11 of 24 evaluable patients during the primary regimen and in additional two patients following booster injections. Two patients responded to HR2822. Cloned GV1001-specific CD4+ T cells displayed a Th1 cytokine profile and recognized autologous antigen presenting cells pulsed with recombinant telomerase protein. A complete tumor response was observed in one patient who developed GV1001-specific cytotoxic T cells that could be cloned from peripheral blood. Conclusion: The results demonstrate that GV1001 and HR2822 are immunogenic and safe to use in patients with NSCLC. Induction of GV1001-specific immune responses may result in objective tumor responses. Based on these initial encouraging results, further clinical studies of GV1001 in NSCLC patients are warranted.Keywords
This publication has 27 references indexed in Scilit:
- Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patientsExperimental Hematology, 2005
- Autologous Dendritic Cell Vaccines for Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Immunization of Patients with the hTERT:540-548 Peptide Induces Peptide-Reactive T Lymphocytes That Do Not Recognize Tumors Endogenously Expressing TelomeraseClinical Cancer Research, 2004
- Vaccination of Cancer Patients Against Telomerase Induces Functional Antitumor CD8+ T LymphocytesClinical Cancer Research, 2004
- American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003Journal of Clinical Oncology, 2004
- The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patients with nonsmall cell lung carcinomaCancer, 2003
- Identification of human telomerase reverse transcriptase–derived peptides that induce HLA-A24–restricted antileukemia cytotoxic T lymphocytesBlood, 2001
- Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinomaInternational Journal of Cancer, 2001
- Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sectionsOncogene, 1999
- Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants.Proceedings of the National Academy of Sciences, 1992